DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Clinical trial NCT03529110 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03529110
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-09
- Primary completion
- 2021-05-21
- Enrollment
- 524
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.